Jun 2026 (Q2 FY26) — Aug 11, 2026
Stereotaxis Q2 FY26 — Commercial Inflection Point with New Product Ecosystem
Read the full callStereotaxis (STXS) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Stereotaxis earnings: last reported Tue, 11 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 7.7 | −12.8% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -59.6 | −14.4 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -4.5 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$1.01 0.00% · $0
Performance −66.2% 1Y
1Y: $2.99 on 17 Oct 2025 → $1.01. High $3.1 (20 Oct 2025), low $1.01 (16 Oct 2026).
- Previous close
- $1.01
- 52-week range
- $1.01 – $3.1
- One year
- −67.42%
Overview
- Symbol
- STXS
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Stereotaxis earnings calls (STXS)
Financials
What the filings say
Net profit, year on year: −17% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 9 | 6 | 7 | 9 | 7 | 9 | 6 | 8 |
| Operating profit | -6 | -8 | -6 | -4 | -7 | -6 | -6 | -5 |
| Operating margin | −69.0% | −120.3% | −79.3% | −45.2% | −87.8% | −65.4% | −95.1% | −59.6% |
| Net profit | -6 | -8 | -6 | -4 | -6 | -6 | -6 | -4 |
| EPS ($ per share) | -0.08 | — | -0.07 | -0.05 | -0.07 | — | -0.06 | -0.05 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -477 | -481 | -488 | -499 | -517 | -538 | -562 | -583 |
| Total liabilities | 11 | 15 | 15 | 22 | 21 | 20 | 35 | 34 |
| Fixed assets | 0 | 0 | 0 | 3 | 4 | 3 | 4 | 3 |
| Investments | — | — | — | — | 20 | — | 0 | 0 |
| Total assets | 19 | 44 | 55 | 61 | 53 | 42 | 47 | 52 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -3 | -5 | -4 | -3 | -8 | -9 | -8 | -14 |
| Cash from investing | -0 | -0 | -0 | -1 | -22 | 20 | 0 | -0 |
| Cash from financing | 10 | 24 | 17 | 1 | 0 | 0 | 0 | 15 |
| Net cash flow | 7 | 19 | 14 | -4 | -30 | 11 | -8 | 1 |
| Capital expenditure | -0 | -0 | -0 | -1 | -2 | -0 | -0 | -0 |
| Free cash flow | -3 | -5 | -4 | -4 | -11 | -10 | -9 | -14 |
Insider filings
14 filings between Nov 14, 2025 and Jul 1, 2026.
Open market
decisions to buy or sellPurchases
$66.6K
2 purchases by 1 insider
Sales
None
No insider sold shares.
Compensation
not trading decisions- 12
- Award — granted as compensation
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Isaac Paul J | $66.6K | — | Nov 17, 2025 |
Latest filings (29)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Jul 1, 2026 | Curet Myriam Director | Award | 43,103 | $0 |
| Jul 1, 2026 | Menawat Arun Swarup Director | Award | 43,103 | $0 |
| Jul 1, 2026 | Fischel Nathan Director | Award | 43,103 | $0 |
| Jul 1, 2026 | Levin Ross B Director | Award | 43,103 | $0 |
| Jul 1, 2026 | Benfer David Director | Award | 43,103 | $0 |
| Jul 1, 2026 | SHAMIR NACHUM Director | Award | 43,103 | $0 |
| Jan 2, 2026 | Levin Ross B Director | Award | 46,948 | $0 |
| Jan 2, 2026 | SHAMIR NACHUM Director | Award | 46,948 | $0 |
| Jan 2, 2026 | Fischel Nathan Director | Award | 46,948 | $0 |
| Jan 2, 2026 | Benfer David Director | Award | 46,948 | $0 |
| Jan 2, 2026 | Menawat Arun Swarup Director | Award | 46,948 | $0 |
| Jan 2, 2026 | Curet Myriam Director | Award | 46,948 | $0 |
| Nov 17, 2025 | Isaac Paul J Director | Purchase | 10,000 | $21.8K |
| Nov 14, 2025 | Isaac Paul J Director | Purchase | 20,000 | $44.8K |
| Jul 1, 2025 | SHAMIR NACHUM Director | Award | 43,668 | $0 |
| Jul 1, 2025 | Curet Myriam Director | Award | 43,668 | $0 |
| Jul 1, 2025 | Benfer David Director | Award | 43,668 | $0 |
| Jul 1, 2025 | Levin Ross B Director | Award | 43,668 | $0 |
| Jul 1, 2025 | Fischel Nathan Director | Award | 43,668 | $0 |
| Jul 1, 2025 | Menawat Arun Swarup Director | Award | 43,668 | $0 |
| Mar 10, 2025 | Isaac Paul J Director | Purchase | 38,000 | $68.8K |
| Mar 7, 2025 | Isaac Paul J Director | Purchase | 1,489 | $2.7K |
| Mar 6, 2025 | Isaac Paul J Director | Purchase | 23,299 | $42.2K |
| Jan 2, 2025 | Benfer David Director | Award | 56,497 | $0 |
| Jan 2, 2025 | Fischel Nathan Director | Award | 56,497 | $0 |
| Jan 2, 2025 | Menawat Arun Swarup Director | Award | 56,497 | $0 |
| Jan 2, 2025 | Levin Ross B Director | Award | 56,497 | $0 |
| Jan 2, 2025 | SHAMIR NACHUM Director | Award | 45,608 | $0 |
| Jan 2, 2025 | Curet Myriam Director | Award | 56,497 | $0 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Stereotaxis, Inc.
Free account. Everything above stays public.
Write why you follow Stereotaxis, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading